Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2026-01-14 00:00:00 ET · period of report 2026-01-12 · accession 0001793412-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-14 | 2026-01-12 | TSHA | Alam Kamran | CFO | A - Grant | $0.00 | +359.0K | 1.55M | +30% | $0 |
| D | 2026-01-14 | 2026-01-12 | TSHA | Alam Kamran | CFO | A - Grant | $0.00 | +231.0K | 231.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-12 | A | A | 359,000 | $0.00 | 1,546,603 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2026-01-12 | A | A | 231,000 | $0.00 | 231,000 | D | $4.86 · — to 2036-01-12 | 231,000 Common Stock | (F2) 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |